Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.08
NAS:BMRN's Cash-to-Debt is ranked lower than
81% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:BMRN: 1.08 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BMRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 1.14 Max: No Debt
Current: 1.08
Equity-to-Asset 0.70
NAS:BMRN's Equity-to-Asset is ranked higher than
53% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:BMRN: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BMRN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.66  Med: 0.61 Max: 0.97
Current: 0.7
-0.66
0.97
Debt-to-Equity 0.24
NAS:BMRN's Debt-to-Equity is ranked higher than
53% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:BMRN: 0.24 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:BMRN' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.98  Med: 0.43 Max: 15.68
Current: 0.24
-3.98
15.68
Piotroski F-Score: 5
Altman Z-Score: 8.06
Beneish M-Score: -2.39
WACC vs ROIC
13.06%
-6.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -17.38
NAS:BMRN's Operating Margin % is ranked higher than
54% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:BMRN: -17.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BMRN' s Operating Margin % Range Over the Past 10 Years
Min: -71.94  Med: -12.42 Max: 13.41
Current: -17.38
-71.94
13.41
Net Margin % -14.54
NAS:BMRN's Net Margin % is ranked higher than
56% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:BMRN: -14.54 )
Ranked among companies with meaningful Net Margin % only.
NAS:BMRN' s Net Margin % Range Over the Past 10 Years
Min: -56.43  Med: -15.44 Max: 54.7
Current: -14.54
-56.43
54.7
ROE % -6.77
NAS:BMRN's ROE % is ranked higher than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:BMRN: -6.77 )
Ranked among companies with meaningful ROE % only.
NAS:BMRN' s ROE % Range Over the Past 10 Years
Min: -24.39  Med: -9.05 Max: 39.6
Current: -6.77
-24.39
39.6
ROA % -4.62
NAS:BMRN's ROA % is ranked higher than
63% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:BMRN: -4.62 )
Ranked among companies with meaningful ROA % only.
NAS:BMRN' s ROA % Range Over the Past 10 Years
Min: -16.26  Med: -4.87 Max: 18.88
Current: -4.62
-16.26
18.88
ROC (Joel Greenblatt) % -18.95
NAS:BMRN's ROC (Joel Greenblatt) % is ranked higher than
64% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:BMRN: -18.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BMRN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -89.45  Med: -11.53 Max: 31.1
Current: -18.95
-89.45
31.1
3-Year Revenue Growth Rate 19.10
NAS:BMRN's 3-Year Revenue Growth Rate is ranked higher than
72% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:BMRN: 19.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BMRN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.4  Med: 13.2 Max: 97.3
Current: 19.1
-10.4
97.3
3-Year EBITDA Growth Rate 61.80
NAS:BMRN's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:BMRN: 61.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BMRN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.2  Med: 25.65 Max: 424.8
Current: 61.8
-45.2
424.8
3-Year EPS without NRI Growth Rate 43.80
NAS:BMRN's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:BMRN: 43.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BMRN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.75 Max: 43.8
Current: 43.8
0
43.8
GuruFocus has detected 1 Warning Sign with Biomarin Pharmaceutical Inc $NAS:BMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BMRN's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BMRN Guru Trades in Q3 2016

Jana Partners 52,890 sh (New)
George Soros 5,734 sh (New)
Ray Dalio 8,926 sh (New)
Andreas Halvorsen 490,304 sh (New)
Steven Cohen 153,700 sh (New)
Manning & Napier Advisors, Inc 142,410 sh (+1.78%)
John Griffin 800,000 sh (unchged)
Joel Greenblatt Sold Out
PRIMECAP Management 7,108,129 sh (-2.89%)
Frank Sands 10,221,282 sh (-6.38%)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (-21.07%)
» More
Q4 2016

BMRN Guru Trades in Q4 2016

Jim Simons 39,371 sh (New)
Manning & Napier Advisors, Inc 2,027,930 sh (+1324.01%)
Steven Cohen 526,600 sh (+242.62%)
Andreas Halvorsen 1,398,457 sh (+185.22%)
Jana Partners 93,923 sh (+77.58%)
PRIMECAP Management 7,885,948 sh (+10.94%)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (unchged)
Ray Dalio Sold Out
George Soros Sold Out
Frank Sands 9,380,802 sh (-8.22%)
John Griffin 595,000 sh (-25.63%)
» More
Q1 2017

BMRN Guru Trades in Q1 2017

PRIMECAP Management 8,712,268 sh (+10.48%)
John Griffin 595,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 292,429 sh (unchged)
Jim Simons Sold Out
Jana Partners 92,030 sh (-2.02%)
Frank Sands 8,972,405 sh (-4.35%)
Manning & Napier Advisors, Inc 1,692,470 sh (-16.54%)
Steven Cohen 364,800 sh (-30.73%)
Andreas Halvorsen 876,113 sh (-37.35%)
» More
Q2 2017

BMRN Guru Trades in Q2 2017

George Soros 2,500 sh (New)
Paul Tudor Jones 16,267 sh (New)
Jim Simons 126,871 sh (New)
Manning & Napier Advisors, Inc 2,118,486 sh (+25.17%)
PRIMECAP Management 9,310,224 sh (+6.86%)
Jana Partners Sold Out
Steven Cohen Sold Out
Frank Sands 8,505,481 sh (-5.20%)
John Griffin 563,800 sh (-5.24%)
Andreas Halvorsen 259,656 sh (-70.36%)
Eaton Vance Worldwide Health Sciences Fund 226,353 sh (-22.60%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-06-30 New Buy0.01%$86.03 - $98.82 $ 93.202%2,500
George Soros 2016-12-31 Sold Out 0.02%$78.62 - $95.92 $ 93.208%0
George Soros 2016-09-30 New Buy0.02%$79.86 - $101.46 $ 93.20-1%5,734
Joel Greenblatt 2016-09-30 Sold Out $79.86 - $101.46 $ 93.20-1%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALNY, NAS:KITE, NAS:INCY, NAS:SGEN, NAS:EXEL, NAS:TSRO, NAS:IONS, NAS:BIVV, NAS:BLUE, NAS:NBIX, NAS:UTHR, NAS:JUNO, NAS:ACAD, NAS:TECH, NAS:PBYI, NAS:CLVS, NAS:FGEN, NAS:NKTR, NAS:AGIO, NAS:PTLA » details
Traded in other countries:BMRN.Austria, BM8.Germany,
Headquarter Location:USA
Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme and Vimizim independently. BioMarin markets Kuvan--to treat the rare metabolic disorder PKU--in the U.S., and recently reacquired international rights for Kuvan and PKU drug candidate pegvaliase from Merck KGaA. BioMarin expanded its pipeline with acquisitions in 2010 ( LEAD Therapeutics and Zystor) and 2015 (Prosensa).

Top Ranked Articles about Biomarin Pharmaceutical Inc

FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA)
BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017
BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017
FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation
BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024
Forbes Ranks BioMarin 12th Most Innovative Company in the World
BioMarin to Attend Upcoming Investor Conferences
BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024
BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies

Ratios

vs
industry
vs
history
Forward PE Ratio 400.00
BMRN's Forward PE Ratio is ranked lower than
99.99% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. BMRN: 400.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 5.92
BMRN's PB Ratio is ranked lower than
65% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BMRN: 5.92 )
Ranked among companies with meaningful PB Ratio only.
BMRN' s PB Ratio Range Over the Past 10 Years
Min: 3.67  Med: 6.26 Max: 20.7
Current: 5.92
3.67
20.7
PS Ratio 13.56
BMRN's PS Ratio is ranked lower than
52% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. BMRN: 13.56 )
Ranked among companies with meaningful PS Ratio only.
BMRN' s PS Ratio Range Over the Past 10 Years
Min: 3.38  Med: 13.59 Max: 31.59
Current: 13.56
3.38
31.59
EV-to-EBIT -80.94
BMRN's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. BMRN: -80.94 )
Ranked among companies with meaningful EV-to-EBIT only.
BMRN' s EV-to-EBIT Range Over the Past 10 Years
Min: -2242  Med: -60.55 Max: 305.6
Current: -80.94
-2242
305.6
EV-to-EBITDA -142.13
BMRN's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BMRN: -142.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26007  Med: -80.1 Max: 1532.3
Current: -142.13
-26007
1532.3
EV-to-Revenue 13.79
BMRN's EV-to-Revenue is ranked lower than
51% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. BMRN: 13.79 )
Ranked among companies with meaningful EV-to-Revenue only.
BMRN' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.3  Med: 13.8 Max: 31.2
Current: 13.79
3.3
31.2
Current Ratio 3.90
BMRN's Current Ratio is ranked lower than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. BMRN: 3.90 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.22 Max: 18.94
Current: 3.9
0.9
18.94
Quick Ratio 2.75
BMRN's Quick Ratio is ranked lower than
59% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. BMRN: 2.75 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 5.21 Max: 18.77
Current: 2.75
0.82
18.77
Days Inventory 608.26
BMRN's Days Inventory is ranked lower than
97% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. BMRN: 608.26 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s Days Inventory Range Over the Past 10 Years
Min: 367.05  Med: 530.66 Max: 608.26
Current: 608.26
367.05
608.26
Days Sales Outstanding 72.42
BMRN's Days Sales Outstanding is ranked lower than
53% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. BMRN: 72.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.96  Med: 74.4 Max: 86.7
Current: 72.42
50.96
86.7

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
BMRN's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. BMRN: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.6  Med: -9.05 Max: -3.2
Current: -6.4
-32.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 69.55
BMRN's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. BMRN: 69.55 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BMRN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.95  Med: 21.51 Max: 208.24
Current: 69.55
2.95
208.24
Price-to-Tangible-Book 7.93
BMRN's Price-to-Tangible-Book is ranked lower than
68% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BMRN: 7.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMRN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.13  Med: 7.54 Max: 116.7
Current: 7.93
2.13
116.7
Price-to-Median-PS-Value 0.98
BMRN's Price-to-Median-PS-Value is ranked higher than
53% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. BMRN: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMRN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.31 Max: 11.09
Current: 0.98
0.3
11.09
Earnings Yield (Greenblatt) % -1.23
BMRN's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. BMRN: -1.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMRN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.7  Med: -1 Max: 4.1
Current: -1.23
-5.7
4.1

More Statistics

Revenue (TTM) (Mil) $1,201.18
EPS (TTM) $ -1.00
Beta1.85
Short Percentage of Float5.26%
52-Week Range $78.42 - 100.51
Shares Outstanding (Mil)175.27

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,311 1,498 1,732 2,058
EPS ($) -0.43 0.18 0.76 2.12
EPS without NRI ($) -0.43 0.18 0.76 2.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
76.00%
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}